Johnson & Johnson (JNJ) is Newman Dignan & Sheerar Inc.’s 7th Largest Position

Newman Dignan & Sheerar Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,126 shares of the company’s stock after selling 359 shares during the quarter. Johnson & Johnson makes up approximately 2.5% of Newman Dignan & Sheerar Inc.’s investment portfolio, making the stock its 7th largest position. Newman Dignan & Sheerar Inc.’s holdings in Johnson & Johnson were worth $4,697,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. State Street Corp raised its holdings in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the last quarter. FMR LLC raised its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors raised its holdings in Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after buying an additional 1,050,000 shares during the last quarter. 65.70% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on JNJ shares. Cowen set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, August 24th. BMO Capital Markets reiterated a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. UBS reiterated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Citigroup raised their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $145.51.

Shares of Johnson & Johnson (JNJ) opened at $141.16 on Thursday. The firm has a market cap of $381,136.59, a P/E ratio of 19.87, a price-to-earnings-growth ratio of 2.88 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.68 EPS. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/21/johnson-johnson-jnj-is-newman-dignan-sheerar-inc-s-7th-largest-position.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply